We discuss the importance of comparator medicines in Arena International's 2023 Outsourcing in Clinical Trials handbook
Our article entitled ‘Budgeting for Clinical Trials: The Importance of Comparator Medicines’ appears in the 2023 Outsourcing in Clinical Trials (OCT) handbook by Arena International.
Due to the growing number of global trials, and their increasing complexity, as well as drug shortages becoming more prevalent, sourcing comparator drugs has become more difficult.
With over 25 years of experience supplying clinical trials, we have gained a deep understanding of the availability of comparator drugs across the globe and what considerations organisations should take when creating their clinical trial budget.
The OCT handbook is the go-to guide for professionals in the global clinical outsourcing space, with insights from leading industry experts, including Clinical Services International (CSI).
What we highlight
General considerations when preparing a clinical trial budget
Ethical considerations and competition among clinical trials driving comparator demand
Factors to consider when building your comparator sourcing budget
Risk mitigation in comparator sourcing
As the article explains, budgeting for comparator drugs isn’t a simple process, with numerous potential pitfalls. As a result, having a comparator drugs supplier who can overcome these challenges is essential.
With our network of over 95 manufacturers across more than 50 countries and six continents, CSI can optimise your comparator sourcing strategy and ensure that high-quality, on-time, and on-budget comparator drugs are delivered to your clinical trial.
If you enjoyed reading our article and want to discuss your clinical trial requirements with CSI, please contact us today.